PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance.

Thorac Cancer · 2026 · PMC12885618 · PMID 41663093

Europe PMC DOI

hedged sentence

0.0740

closest p · 1.5× alpha

0.0740

boldest claim

The sentences

a nonsignificant trendp = 0.074so close (0.05 < p ≤ 0.1)

After PSM, median PFS was 23.0 months (95% CI: 12.1–53.1) in the PD‐L1 < 50% group versus 4.5 months (95% CI: 2.7–19.8) in the ≥ 50% group, showing a nonsignificant trend toward shorter PFS (HR: 1.84; 95% CI: 0.93–3.63, p = 0.074) (Figure 3A ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.